Free Novo Nordisk Assessment Practice Questions

Question 1

The Novo Nordisk Foundation, through Novo Holdings A/S, controls Novo Nordisk A/S. Which statement BEST describes how that control operates?

Accepted Answer

It holds a minority of the share capital but a majority of the voting rights, via dual-class shares

Answer

It owns a majority of the share capital, and therefore commands a majority of votes at general meetings

Answer

It owns all of the listed B shares, which carry ten times the voting power of the unlisted A shares

Answer

It holds no shares at all, but has the right to appoint the chair and a majority of the board directly

Question 2

Which statement about the Novo group of entities is correct?

Accepted Answer

Novo Holdings A/S is the investment arm, wholly owned by the Novo Nordisk Foundation

Answer

The Novo Nordisk Foundation is the charitable giving division within Novo Nordisk A/S's corporate affairs function

Answer

NNE A/S is the in-house engineering department of Novo Nordisk A/S

Answer

Novonesis is the enzymes and biosolutions division of Novo Nordisk A/S

Question 3

In FY2025 Novo Nordisk reported sales growth of 6% in Danish kroner but 10% at constant exchange rates (CER). What does this difference indicate?

Accepted Answer

Currency movements reduced reported growth below underlying growth

Answer

The company divested roughly 4% of its revenue base during the year

Answer

Total growth was 16%, combining underlying volume growth and currency gains

Answer

The kroner figure is the truer measure, since CER excludes real costs incurred in local markets

Question 4

An interviewer asks: "What do you see as the biggest commercial challenge facing Novo Nordisk right now?" Which response is BEST supported by the company's FY2025 reporting and FY2026 guidance?

Accepted Answer

Pricing pressure and competition, with adjusted operating profit guided to decline in 2026

Answer

Manufacturing capacity constraints that continue to limit the supply of semaglutide products

Answer

A shortage of qualified scientific staff following the 2025 restructuring

Answer

The absence of any late-stage obesity candidates in the company's pipeline

Question 5

Ozempic, Rybelsus and Wegovy all contain semaglutide. Which statement correctly distinguishes Wegovy?

Accepted Answer

It is semaglutide 2.4 mg, indicated for chronic weight management

Answer

It is the oral formulation, whereas the other two are administered by injection

Answer

It is the only one of the three that is approved for type 2 diabetes

Answer

It combines semaglutide with cagrilintide in a single injection

Question 6

Novo Nordisk has run several major cardiovascular outcomes trials. Which one was the first to demonstrate a reduction in major adverse cardiovascular events (MACE) for an ORAL GLP-1 receptor agonist?

Accepted Answer

SOUL

Answer

LEADER

Answer

PIONEER

Answer

SELECT

Question 7

CagriSema, one of Novo Nordisk's most closely watched pipeline assets, combines semaglutide with which other agent?

Accepted Answer

Cagrilintide, an amylin analogue

Answer

Cagrilintide, a GIP receptor agonist

Answer

Concizumab, an anti-TFPI antibody

Answer

Somapacitan, a long-acting growth hormone

Question 8

Novo Nordisk markets both Norditropin and Sogroya for growth hormone therapy. What is the principal difference between them?

Accepted Answer

Norditropin is administered daily, whereas Sogroya is administered once weekly

Answer

Norditropin is a biosimilar, whereas Sogroya is the originator product

Answer

Norditropin treats haemophilia, whereas Sogroya treats growth disorders

Answer

Norditropin is approved only in Europe, whereas Sogroya is approved only in the US

Question 9

Which of the following is, word for word, one of the ten Essentials of the Novo Nordisk Way?

Accepted Answer

We strive for agility and simplicity in everything we do

Answer

We act with integrity in every decision we make

Answer

We put safety first in everything we do

Answer

We are committed to continuous improvement across all of our operations

Question 10

A project team is under pressure to meet a launch date. A team member proposes shortening a validation step to save two weeks, arguing that this reflects the Essential on agility and simplicity. How should this be resolved under the Novo Nordisk Way?

Accepted Answer

Quality and ethics are never compromised; agility cannot override that requirement

Answer

Agility and simplicity take precedence, since the Essentials are ranked in priority order

Answer

The proposal is acceptable if the time saved is documented and the risk formally accepted

Answer

The team should escalate the decision to Executive Management for a ruling

Free Novo Nordisk Assessment Practice Questions

Question 1

Question 2

Question 3

Question 4

Question 5

Question 6

Question 7

Question 8

Question 9

Question 10

What's on the Novo Nordisk Assessment exam

That's 10 of 1,030